Preparation, Characterization, and Oral Bioavailability of Solid Dispersions of Cryptosporidium parvum Alternative Oxidase Inhibitors

Yongxiang Zhang,Minglang Ma,Jinyu Yang,Xiaotong Qiu,Lin Xin,Yixing Lu,Huiguo Huang,Zhenling Zeng,Dongping Zeng

DOI: https://doi.org/10.3390/ijms25137025

IF: 5.6

2024-06-27

International Journal of Molecular Sciences

Abstract:The phenylpyrazole derivative 5-amino-3-[1-cyano-2-(3-phenyl-1H-pyrazol-4-yl) vinyl]-1-phenyl-1H-pyrazole-4-carbonitrile (LN002), which was screened out through high-throughput molecular docking for the AOX target, exhibits promising efficacy against Cryptosporidium. However, its poor water solubility limits its oral bioavailability and therapeutic utility. In this study, solid dispersion agents were prepared by using HP-β-CD and Soluplus® and characterized through differential scanning calorimetry, Fourier transform infrared, powder X-ray diffraction, and scanning electron microscopy. Physical and chemical characterization showed that the crystal morphology of LN002 transformed into an amorphous state, thus forming a solid dispersion of LN002. The solid dispersion prepared with an LN002/HP-β-CD/Soluplus® mass ratio of 1:3:9 (w/w/w) exhibited significantly increased solubility and cumulative dissolution. Meanwhile, LN002 SDs showed good preservation stability under accelerated conditions of 25 °C and 75% relative humidity. The complexation of LN002 with HP-β-CD and Soluplus® significantly improved water solubility, pharmacological properties, absorption, and bioavailability.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the water - solubility and oral bioavailability of LN002 (5 - amino - 3 - [1 - cyano - 2 - (3 - phenyl - 1H - pyrazol - 4 - yl)ethenyl]-1 - phenyl - 1H - pyrazole - 4 - carbonitrile). LN002 is an effective inhibitor against Cryptosporidium alternative oxidase (CpAOX) screened by high - throughput molecular docking, and has good anti - infective activity against Cryptosporidium. However, due to its extremely low water - solubility, the oral bioavailability and therapeutic application of LN002 are limited.

To overcome this problem, the researchers prepared solid dispersions of LN002 and used hydroxypropyl - β - cyclodextrin (HP - β - CD) and Soluplus® as carrier materials. Specifically, the main objectives of the study include:

1. **Improve solubility**: Significantly increase the solubility of LN002 in water by preparing solid dispersions.
2. **Improve pharmacokinetic characteristics**: Increase the oral bioavailability of LN002, thereby enhancing its therapeutic effect.
3. **Maintain stability**: Ensure the long - term stability of the solid dispersion under accelerated conditions to guarantee the quality and effectiveness of the drug.

Through these improvements, the researchers hope to provide a more effective and easier - to - take drug form for the treatment of Cryptosporidium infection.